 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...251252253254255256257258259260261...266267» |
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (clinicaltrials.gov) - Sep 17, 2015
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Trial completion, Enrollment change, Combination therapy, Metastases: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (clinicaltrials.gov) - Sep 16, 2015
P1, N=38, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=72 --> 38
- Vesanoid (tretinoin) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Metastases: Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=60, Not yet recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | N=72 --> 38 Initiation date: Mar 2015 --> Mar 2016
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Sep 16, 2015
P2/3, N=400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2015 --> Mar 2016 Initiation date: Mar 2015 --> Oct 2015
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Metastases: KEYNOTE 029: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (clinicaltrials.gov) - Sep 14, 2015
P1/2, N=343, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Mar 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- |||||||||| Yervoy (ipilimumab) / BMS
New P3 trial, Metastases: A Comparative Study in Chinese Subjects With Chemotherapy Na (clinicaltrials.gov) - Sep 9, 2015
P3, N=180, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Metastases: A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (clinicaltrials.gov) - Sep 4, 2015
P1, N=20, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=36 --> 20
- ||||||| Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Sep 4, 2015
P3, N=602, Completed, Sponsor: Bristol-Myers Squibb
N=36 --> 20 Active, not recruiting --> Completed
- |||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment open, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers (clinicaltrials.gov) - Sep 4, 2015
P1/2, N=120, Recruiting, Sponsor: Boston Biomedical, Inc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Sep 3, 2015
P1, N=600, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=270 --> 600 | Trial primary completion date: Jul 2018 --> Dec 2018
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 3, 2015
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
N=270 --> 600 | Trial primary completion date: Jul 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Sep 3, 2015
P1, N=85, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, Tumor mutational burden, PD(L)-1 Biomarker: CheckMate 451: An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (clinicaltrials.gov) - Sep 2, 2015
P3, N=810, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Aug 27, 2015
P1, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016 N=23 --> 70
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov) - Aug 27, 2015
P2, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
N=23 --> 70 Suspended --> Recruiting
- ||| lefitolimod (MGN1703) / Feng Biosci, iPharma, Gilead, Yervoy (ipilimumab) / BMS
New P1 trial, Metastases: A Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 25, 2015
P1, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (clinicaltrials.gov) - Aug 24, 2015
P1, N=72, Active, not recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Sep 2015
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 227: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 21, 2015
P3, N=1980, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Sep 2015 Trial primary completion date: Dec 2020 --> May 2017
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 238: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (clinicaltrials.gov) - Aug 21, 2015
P3, N=800, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2020 --> May 2017 Trial primary completion date: Jun 2019 --> Nov 2018
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 21, 2015
P2, N=120, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 20, 2015
P1/2, N=1100, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2019 --> Nov 2018 N=410 --> 1100
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na (clinicaltrials.gov) - Aug 20, 2015
P1/2, N=57, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=410 --> 1100 Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - Aug 20, 2015
P1, N=412, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=20, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Aug 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden, PD(L)-1 Biomarker: A091401: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 19, 2015
P2, N=84, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Aug 2016 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Aug 19, 2015
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: IMMUNED: Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED (clinicaltrials.gov) - Aug 14, 2015
P2, N=312, Recruiting, Sponsor: Prof. Dr. med. Dirk Schadendorf
- || epacadostat (INCB024360) / Incyte
Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=136, Active, not recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Feb 2016
- || Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab + Temozolomide in Metastatic Melanoma (clinicaltrials.gov) - Aug 13, 2015
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2014 --> Feb 2016 Trial primary completion date: May 2016 --> May 2017
- || Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=2500, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2016 --> May 2017 Initiation date: Sep 2014 --> Oct 2013
- Trial initiation date, Trial primary completion date: Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) - Aug 13, 2015
P1, N=12, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Sep 2014 --> Oct 2013 Initiation date: Jul 2015 --> Nov 2015 | Trial primary completion date: Jul 2018 --> Nov 2018
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Phase classification, IO biomarker: Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (clinicaltrials.gov) - Aug 12, 2015
P0, N=28, Active, not recruiting, Sponsor: Ahmad Tarhini
Initiation date: Jul 2015 --> Nov 2015 | Trial primary completion date: Jul 2018 --> Nov 2018 Phase classification: P=N/A --> P0
- Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, Metastases: Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (clinicaltrials.gov) - Aug 12, 2015
P2, N=25, Active, not recruiting, Sponsor: National Center for Tumor Diseases, Heidelberg
Phase classification: P=N/A --> P0 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2015
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial termination, Trial primary completion date, Metastases: Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (clinicaltrials.gov) - Aug 12, 2015
P2, N=10, Terminated, Sponsor: New York University School of Medicine
N=100 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Mar 2015; Study terminated because PI left institution. Planned Statistical analysis not available
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Phase classification, Combination therapy, Metastases: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Aug 12, 2015
P1, N=30, Recruiting, Sponsor: Ahmad Tarhini
Planned Statistical analysis not available Phase classification: P=N/A --> P1
- Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Aug 11, 2015
P1, N=96, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P=N/A --> P1 Recruiting --> Active, not recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Aug 10, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Adverse events, Metastases: Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (clinicaltrials.gov) - Aug 7, 2015
P=N/A, N=25, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Monotherapy: CheckMate 204: An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (clinicaltrials.gov) - Aug 6, 2015
P2, N=110, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=148 --> 110 | Trial primary completion date: Mar 2018 --> Jun 2018
- | Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Metastases: A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (clinicaltrials.gov) - Aug 6, 2015
P1, N=36, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | PD(L)-1 Biomarker, IO biomarker: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Aug 5, 2015
P3, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
N=148 --> 110 | Trial primary completion date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jul 2015
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CheckMate 227: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 23, 2015
P3, N=1980, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
New P2 trial, Monotherapy: Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (clinicaltrials.gov) - Jul 22, 2015
P2, N=75, Not yet recruiting, Sponsor: University of California, San Francisco
- lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (clinicaltrials.gov) - Jul 22, 2015
P1, N=22, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=125 --> 22 | Trial primary completion date: Mar 2016 --> Apr 2015
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date: YERVOY (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=158, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=125 --> 22 | Trial primary completion date: Mar 2016 --> Apr 2015 Initiation date: Mar 2015 --> Jul 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Jul 20, 2015
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2015 --> Jul 2015 Suspended --> Recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Trial termination, Trial primary completion date, Metastases: PROCLIVITY 02: HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 17, 2015
P4, N=29, Terminated, Sponsor: Prometheus Laboratories
Suspended --> Recruiting N=100 --> 29 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; slow accrual & early closure
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker: A091401: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 17, 2015
P2, N=84, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial primary completion date: Study of Ipilimumab in the Immune System (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=4, Active, not recruiting, Sponsor: University Health Network, Toronto
N=100 --> 29 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2015; slow accrual & early closure Not yet recruiting --> Active, not recruiting | N=30 --> 4 | Trial primary completion date: Oct 2014 --> Oct 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial suspension, PD(L)-1 Biomarker: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=37, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting | N=30 --> 4 | Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Suspended